Compare NEU & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEU | NUVL |
|---|---|---|
| Founded | 1887 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.1B |
| IPO Year | N/A | 2021 |
| Metric | NEU | NUVL |
|---|---|---|
| Price | $647.28 | $105.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $135.00 |
| AVG Volume (30 Days) | 149.1K | ★ 548.0K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 5.10 | N/A |
| EPS | ★ 47.34 | N/A |
| Revenue | ★ $2,744,413,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $480.57 | $55.54 |
| 52 Week High | $875.97 | $112.88 |
| Indicator | NEU | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 54.35 |
| Support Level | $691.17 | $97.43 |
| Resistance Level | $730.51 | $108.65 |
| Average True Range (ATR) | 23.07 | 4.63 |
| MACD | -3.51 | 0.48 |
| Stochastic Oscillator | 14.88 | 79.92 |
NewMarket Corp is a holding company that, through its subsidiaries, manufactures and sells petroleum additives. Petroleum additives are used in lubricating oils and fuels to enhance their performance in machinery, vehicles, and other equipment. It comprises two broad product applications. Lubricant additives are formulated chemical solutions that, when blended with base fluids, improve the efficiency, durability, performance, and functionality of mineral oils, synthetic oils, and biodegradable fluids. Fuel additives are chemical components that help oil refiners meet fuel specifications or formulated packages that improve the performance of gasoline, diesel, biofuels, and other fuels.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.